Cargando…
Hyperprogression: A novel response pattern under immunotherapy
Checkpoint blockade therapy has shown significant therapeutic benefits and resulted in durable responses in patients with various tumors. However, accumulating evidence has demonstrated that 4‐29% of all patients with cancers with various histologies may suffer from tumor flare following such therap...
Autores principales: | Han, Xue‐jiao, Alu, Aqu, Xiao, Yi‐nan, Wei, Yu‐quan, Wei, Xia‐wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510779/ https://www.ncbi.nlm.nih.gov/pubmed/32997401 http://dx.doi.org/10.1002/ctm2.167 |
Ejemplares similares
-
Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019) -
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022) -
Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review
por: Lin, Miaozhen, et al.
Publicado: (2021) -
Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019) -
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
por: Alu, Aqu, et al.
Publicado: (2022)